Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Crizotinib in ALK Rearranged Non-small-cell Lung Cancer

NCT04317651 is registered in ClinicalTrials.gov with Fondazione Ricerca Traslazionale as lead sponsor.

NCT NCT04317651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04317651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Crizotinib in ALK Rearranged Non-small-cell Lung Cancer
Lead sponsor
Fondazione Ricerca Traslazionale
Phase
Observational
Overall status
Unknown status
Start date
May 16, 2019
Completion date
June 30, 2022
Enrollment
500 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, non small cell lung cancer